Diterpene Glycosides from Fructus Rubi: Dual Modulation of Androgen and TGF-β/Smad Pathways in Benign Prostatic Hyperplasia

Study Background and Research Question

Benign prostatic hyperplasia (BPH) is a common age-related condition characterized by non-malignant enlargement of the prostate, often leading to lower urinary tract symptoms and decreased quality of life in aging males. Central to BPH pathogenesis are disruptions in androgen signaling—particularly involving dihydrotestosterone (DHT)—and aberrant activation of the TGF-β/Smad pathway, which together drive epithelial proliferation and epithelial-mesenchymal transition (EMT). While 5α-reductase inhibitors like finasteride target androgen signaling, limitations such as partial efficacy and side effects prompt ongoing search for novel, multitarget therapies. The reference study (Jundong Yu et al., 2025) addresses whether diterpene glycosides extracted from Fructus Rubi (Rubus chingii Hu), a traditional Chinese medicinal fruit, can ameliorate BPH by targeting both androgen and TGF-β/Smad signaling networks.

Key Innovation from the Reference Study

The primary innovation lies in the dual-action mechanism of the standardized Fructus Rubi diterpene glycoside extract (FDS), demonstrated to suppress both androgen receptor signaling and TGF-β/Smad pathway activity in BPH models. Unlike monotherapies that focus solely on androgen suppression, the study reveals that FDS not only reduces DHT-induced proliferation of prostatic epithelial cells but also regulates EMT through S100A2-mediated modulation of TGF-β/Smad signaling. This multitargeted approach positions FDS as a promising candidate for BPH interventions where hormonal and fibrotic pathways are co-activated.

Methods and Experimental Design Insights

The investigators employed a rigorous experimental design encompassing both in vitro and in vivo models:

• Cellular Assays: Human RWPE-1 prostatic epithelial cells were exposed to DHT to model androgen-driven proliferation. FDS was administered to assess anti-proliferative effects and modulation of key protein markers.
• Animal Model: BPH was induced in rats via subcutaneous injection of testosterone propionate, a protocol known to elevate local DHT and recapitulate prostate enlargement.
• Protein Target Identification: Drug affinity responsive target stability (DARTS) combined with mass spectrometry was applied to screen for FDS-binding proteins, providing mechanistic links between phytochemical constituents and molecular targets.
• Biochemical and Histological Analyses: Serum and prostate DHT levels were quantified using ELISA. Western blotting, immunohistochemistry, and immunofluorescence were employed to evaluate expression of androgen receptor (AR), prostate-specific antigen (PSA), steroid 5α-reductase type 2 (SRD5A2), proliferating cell nuclear antigen (PCNA), S100A2, TGF-β1, E-cadherin, vimentin, and Smad4.

This multi-tiered design enabled robust assessment of FDS effects on both cellular proliferation and fibrotic signaling in BPH.

Protocol Parameters

• DHT induction in cell models: RWPE-1 cells were treated with DHT at concentrations consistent with pathological androgen levels for prostate proliferation modeling.
• BPH induction in rats: Testosterone propionate was injected subcutaneously to sustain elevated DHT and induce prostate enlargement over several weeks.
• FDS administration: Orally administered for 28 days in animal models, with dosage calibrated to reflect effective phytochemical exposure.
• Protein marker assessment: Western blotting, immunohistochemistry, and immunofluorescence for AR, PSA, PCNA, SRD5A2, S100A2, TGF-β1, E-cadherin, vimentin, and Smad4; serum and tissue DHT levels by ELISA.

These parameters support reproducibility and enable extension to related androgenic disease models.

Core Findings and Why They Matter

The study's major findings, as detailed in the reference paper, are:

• FDS significantly inhibits DHT-induced proliferation in RWPE-1 prostatic epithelial cells.
• In vivo, FDS reduces prostate size and DHT concentrations in both serum and prostate tissue of BPH rats.
• FDS downregulates the expression of AR, PSA, SRD5A2, PCNA, and S100A2—key indicators of androgen-driven proliferation.
• FDS modulates the TGF-β/Smad axis by suppressing TGF-β1 and Smad4 while restoring E-cadherin expression and reducing vimentin, signifying reversal of EMT processes that contribute to prostatic fibrosis and hyperplasia.

These findings establish that diterpene glycosides from Fructus Rubi can simultaneously attenuate proliferative and fibrotic drivers of BPH, suggesting a mechanistically grounded, multitarget approach for future preclinical and potentially clinical interventions.

Comparison with Existing Internal Articles

Recent internal resources expand on DHT's role in androgen receptor signaling and its implications for disease modeling. For instance, the article "Dihydrotestosterone (DHT): Advanced Mechanisms in Androgen Receptor and EGFR Pathways" explores how DHT not only acts via the androgen receptor but also intersects with EGFR and ERBB2 pathways, broadening the understanding of androgen-driven cell signaling. Meanwhile, "Dihydrotestosterone (DHT): Mechanistic Evidence & Research Utility" demonstrates DHT's ability to upregulate EGFR and ERBB2 in AR-positive cancer models and its utility in neuromuscular disease research. These articles provide context for the current reference study, highlighting the importance of precise androgen modulation in diverse cellular contexts. Unlike these works, the Fructus Rubi diterpene glycoside study targets both androgen and fibrotic signaling, offering a complementary strategy to model systems reliant solely on DHT-induced pathways.

Limitations and Transferability

While the reference study provides compelling evidence in both cellular and rat models, several limitations must be considered:

• Species and model limitations: Human relevance is inferred but not confirmed; results in RWPE-1 cells and rat BPH models may not fully extrapolate to clinical BPH in humans.
• Extract complexity: The multitarget effects of FDS arise from a mixture of diterpene glycosides, complicating the attribution of activity to individual compounds.
• Mechanistic depth: While the study identifies key protein changes, downstream functional consequences (such as fibrosis progression or reversal) warrant further investigation.

Transferability is promising for preclinical research, particularly for those modeling androgen and EMT-driven prostate disease, but translational application will require further validation in human tissue and clinical trials.

Research Support Resources

Researchers aiming to dissect androgen receptor or EGFR/ERBB2 signaling in BPH or cancer models can utilize purified DHT reagents to establish robust, reproducible in vitro and in vivo protocols. Dihydrotestosterone (DHT) (SKU B8214) from APExBIO provides a well-characterized, high-purity tool for inducing androgen receptor signaling and downstream pathways such as EGFR and AKT phosphorylation in relevant cell lines and animal models. The product dossier details its solubility, storage, and recommended concentrations, supporting applications in cancer biology, neurodegenerative models, and muscle physiology. Integrating such standardized compounds in experimental workflows ensures consistency and comparability with published studies, including those leveraging natural product interventions like Fructus Rubi diterpene glycosides.